⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

February 19, 2024Nuclear Medicine and BiologyOpen Access

In vitro evaluation of [3H]PI-2620 and structural derivatives in non-Alzheimer's tauopathies

Cassis Varlow Chester A. Mathis Neil Vasdev

View Full Paper

Ask AI

Bookmark

Share

Abstract

Alzheimer's disease (AD) and non-AD tauopathies such as chronic traumatic encephalopathy (CTE), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD) are characterized by the abnormal aggregation of three-repeat (3R) and/or four-repeat (4R) tau isoforms. Several tau-PET tracers have been applied for human imaging of AD and non-AD tauopathies including [

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Varlow et al. (2024) studied this question.

synapsesocial.com/papers/68e78948b6db6435876fb290 https://doi.org/10.1016/j.nucmedbio.2024.108891

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Neuronal and oligodendroglial but not astroglial tau translates to in vivo tau-PET signals in primary tauopathies2024 · 4 citations
2The importance of tau tracers in the diagnosis of neurodegenerative diseasesClinical Trial · 2026
3Structure–Activity Relationships and Evaluation of 2-(Heteroaryl-cycloalkyl)-1<i>H</i>-indoles as Tauopathy Positron Emission Tomography RadiotracersOriginal Research · 2025 · 4 citations
4Improved Tau PET SUVR Quantification in 4-Repeat Tau Phenotypes with [<sup>18</sup>F]PI-26202024 · 17 citations
5Combining cerebrospinal fluid and PI‐2620 tau‐PET for biomarker‐based stratification of Alzheimer's disease and 4R‐tauopathies2024 · 23 citations